Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ART101 in hypertension
NCT06780033Phase 1Terminated
- Sponsor
- Arnatar Therapeutics
- Start
- Mar 2025
- Primary completion
- Apr 2025
- Modality
- Conjugated siRNA, Small Molecules, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hypertension (HTN) comparing ART101 SAD with Placebo (2 arms). Primary endpoints: Adverse Events at 365 days, Abnormal Laboratory Values at 365 days and 1 more. Started Mar 2025; status: terminated.
02
Drugs
ART101
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT06780033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06780033.